 Emmaus Life Sciences Inc OTCQX:EMMA has announced its financial results for the three and six months ended June 30, 2022, which received a fillip from the marketing approval in May of its sickle cell disease treatment Endari in the United Arab Emirates UAE. The company reported net revenues of 4.3 million for the second quarter, a rise of nearly 33 compared with the first quarter of 2022, on the back of sales of Endari in the UAE and sales of Endari on an early access basis in Saudi Arabia. 